Cargando…
APOBEC signature mutation generates an oncogenic enhancer that drives LMO1 expression in T-ALL
Oncogenic driver mutations are those that provide a proliferative or survival advantage to neoplastic cells, resulting in clonal selection. Although most cancer-causing mutations have been detected in the protein-coding regions of the cancer genome; driver mutations have recently also been discovere...
Autores principales: | Li, Z, Abraham, B J, Berezovskaya, A, Farah, N, Liu, Y, Leon, T, Fielding, A, Tan, S H, Sanda, T, Weintraub, A S, Li, B, Shen, S, Zhang, J, Mansour, M R, Young, R A, Look, A T |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5629363/ https://www.ncbi.nlm.nih.gov/pubmed/28260788 http://dx.doi.org/10.1038/leu.2017.75 |
Ejemplares similares
-
ZEB2 and LMO2 drive immature T-cell lymphoblastic leukemia via distinct oncogenic mechanisms
por: Goossens, Steven, et al.
Publicado: (2019) -
Oncogenic Lmo3 cooperates with Hen2 to
induce hydrocephalus in mice
por: Isogai, Eriko, et al.
Publicado: (2015) -
ASCL1 is a MYCN- and LMO1-dependent member of the adrenergic neuroblastoma core regulatory circuitry
por: Wang, Lu, et al.
Publicado: (2019) -
JDP2: An oncogenic bZIP transcription factor in T cell acute lymphoblastic leukemia
por: Mansour, Marc R., et al.
Publicado: (2018) -
Conformational flexibility of the oncogenic protein LMO2 primes the formation of the multi-protein transcription complex
por: Sewell, H., et al.
Publicado: (2014)